24/7 Wall Street
04 Jul 2026, 18:00 UTC · 2h ago
Dividend King vs. Growth Giant: Johnson & Johnson Takes on Eli Lilly
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
24/7 Wall Street
04 Jul 2026, 18:00 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Eli Lilly reported a 55.5% year-over-year revenue increase to $19.80 billion for Q1 2026, driven primarily by Mounjaro and Zepbound. — Massive top-line growth and strong demand for GLP-1 drugs validate the company's aggressive growth trajectory.
+0.80Johnson & Johnson plans to spin off its DePuy Synthes orthopaedics business within 18 to 24 months. — Corporate restructuring and divestitures typically unlock value or allow for a more focused, efficient operational strategy.
+0.50Eli Lilly is investing $6 billion in a new Alabama plant and partnering with NVIDIA on a drug-discovery lab to scale its pipeline. — Significant capital expenditure and AI integration indicate long-term capacity expansion and R&D efficiency.
+0.40Continue reading
6 related stories
Top 1 mover · tap to explore
Johnson & Johnson raised its full-year guidance to a revenue range of $100.3 to $101.3 billion and increased its dividend by 3.1%. — Guidance raises and dividend growth provide a positive signal for stability and income-focused investors.
+0.30Eli Lilly's valuation is currently at 33x forward earnings, creating concentrated risk due to heavy reliance on two GLP-1 drugs. — High P/E ratios combined with product concentration increase the stock's vulnerability to any clinical or regulatory setbacks.
-0.20Which stocks this story touches
Reported massive revenue growth of 55.5% driven by GLP-1 drugs and received FDA approval for Foundayo.
Solid revenue growth, raised guidance, and continued its long-term dividend streak.
Mentioned positively through its strategic drug-discovery lab partnership with Eli Lilly.
Mentioned in a related headline but not analyzed in the main text.
Mentioned in a related headline but not analyzed in the main text.
[mutual] Both companies compete in the GLP-1 metabolic drug market.
[mutual] Eli Lilly partnered with NVIDIA on a drug-discovery lab.
[mutual] Both companies are presented as competing playbooks for winning in healthcare.
[mutual] Both companies are mentioned as delivering results in the big pharma sector.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Schwab Network
3h ago
